United Services Automobile Association trimmed its holdings in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 42.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 54,548 shares of the company’s stock after selling 40,974 shares during the period. United Services Automobile Association’s holdings in Pacira Pharmaceuticals were worth $2,347,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also added to or reduced their stakes in PCRX. Vanguard Group Inc lifted its position in shares of Pacira Pharmaceuticals by 7.2% in the third quarter. Vanguard Group Inc now owns 3,641,417 shares of the company’s stock valued at $178,976,000 after buying an additional 243,213 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Pacira Pharmaceuticals by 7.2% in the third quarter. Vanguard Group Inc. now owns 3,641,417 shares of the company’s stock valued at $178,976,000 after buying an additional 243,213 shares during the last quarter. Castleark Management LLC acquired a new stake in shares of Pacira Pharmaceuticals in the third quarter valued at approximately $11,086,000. Baillie Gifford & Co. lifted its position in shares of Pacira Pharmaceuticals by 37.8% in the third quarter. Baillie Gifford & Co. now owns 802,009 shares of the company’s stock valued at $39,418,000 after buying an additional 220,009 shares during the last quarter. Finally, Federated Investors Inc. PA acquired a new stake in shares of Pacira Pharmaceuticals in the third quarter valued at approximately $9,071,000. 97.50% of the stock is owned by institutional investors.
In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld purchased 1,700 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were bought at an average price of $38.97 per share, for a total transaction of $66,249.00. Following the purchase, the director now owns 9,277 shares in the company, valued at approximately $361,524.69. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 5.90% of the company’s stock.
Shares of PCRX opened at $38.22 on Monday. Pacira Pharmaceuticals Inc has a 52-week low of $26.95 and a 52-week high of $55.00. The company has a debt-to-equity ratio of 0.90, a quick ratio of 7.08 and a current ratio of 7.88. The firm has a market capitalization of $1.58 billion, a PE ratio of 131.79, a price-to-earnings-growth ratio of 2.38 and a beta of 1.49.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, February 28th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.21. Pacira Pharmaceuticals had a positive return on equity of 3.94% and a negative net margin of 0.14%. The company had revenue of $95.12 million for the quarter, compared to analyst estimates of $93.69 million. During the same quarter last year, the company posted $0.38 EPS. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Equities research analysts expect that Pacira Pharmaceuticals Inc will post 0.67 earnings per share for the current year.
A number of equities analysts have recently weighed in on PCRX shares. Wedbush set a $91.00 target price on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, January 29th. National Securities assumed coverage on Pacira Pharmaceuticals in a research note on Tuesday, February 12th. They set a “sell” rating on the stock. Mizuho lowered Pacira Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Friday, February 1st. ValuEngine upgraded Pacira Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 2nd. Finally, Stifel Nicolaus restated a “sell” rating and set a $33.00 price objective on shares of Pacira Pharmaceuticals in a research note on Friday, March 8th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $53.25.
ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals Inc (PCRX) Stake Lessened by United Services Automobile Association” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://transcriptdaily.com/2019/03/25/pacira-pharmaceuticals-inc-pcrx-stake-lessened-by-united-services-automobile-association.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Further Reading: What is cost of equity?
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.